Globus Medical Inc (GMED) — Titan Protect Analysis

GMED

Globus Medical Inc

Healthcare · ·

$80.00

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$10.6B

Total market value of the company

Trailing P/E

18.33

Reasonably valued

Forward P/E

15.23

Based on estimated future earnings — lower means cheaper

Rev Growth

+27.0%

Year-over-year revenue change

Profit Margin

18.9%

How much profit the company keeps from each dollar of revenue

ROE

13.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$115.00

+44% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 11 analysts covering this stock

About Globus Medical Inc

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; intervention

https://www.globusmedical.com

Country: United States Employees: 6,000 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.426

Positive but modest risk-adjusted returns

Kelly Fraction

0.0431

Modest edge detected — smaller position warranted

Calmar Ratio

0.223

Drawdown risk outweighs the returns — higher risk profile

Annual Return

9.9%

Historical annualised return based on price data

Max Drawdown

-44.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.00

Moves slightly more than the broader market

52W High

$101.40

21% below the year high

52W Low

$51.79

54% above the year low

Avg Volume

1,366,874

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$4.28

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

2.45

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

68.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

21.3%

Profit from core operations before interest and tax

Free Cash Flow

$341M

Positive — the business generates more cash than it spends

Revenue (TTM)

$3.1B

Total revenue over the last 12 months

Net Income

$587M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$122.00

Target Median

$115.00

Target Low

$87.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go